GDRX
GoodRx Holdings, Inc.2.7600
+0.0500+1.85%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
958.96MP/E (TTM)
34.50Basic EPS (TTM)
0.08Dividend Yield
0%Recent Filings
8-K
8-K
8-K
GoodRx Q2 revenue edges up
GoodRx reported Q2 2025 revenue of $203.1 million, up 1% year-over-year, with pharma manufacturer solutions surging 32% to $35.0 million amid broader healthcare headwinds. Yet prescription transactions dipped 3% to $143.1 million, hit by a 14% drop in monthly active consumers from pharmacy closures and program cuts. Adjusted EBITDA climbed to $69.4 million at a 34.2% margin. Full-year revenue will rise from 2024, but Rite Aid bankruptcy and savings program losses could shave $35-40 million; EBITDA guidance holds at $265-275 million.
10-Q
Q2 FY2025 results
GoodRx's Q2 revenue edged up 1% year-over-year to $203.1 million, fueled by 32% growth in pharma manufacturer solutions that offset a 3% dip in prescription transactions from pharmacy closures and program cuts; operating income climbed 35% to $26.8 million on slimmer sales and marketing costs, while diluted EPS held at $0.04 on 357 million shares. Free cash flow wasn't disclosed in the 10-Q. Cash stood at $281.3 million against $490 million in net debt, with $92.2 million revolver availability and covenant compliance intact; the January 2025 VCRx acquisition for $30 million cash added $11 million goodwill and $18.1 million customer intangibles over 6 years, boosting consumer reach. Yet Rite Aid's bankruptcy lingers as a drag on volumes.
8-K
Annual meeting results
GoodRx Holdings held its annual stockholder meeting on June 3, 2025, with nearly all voting power represented. Stockholders elected Christopher Adams, Trevor Bezdek, and Scott Wagner as Class II directors for terms ending in 2028. They ratified PricewaterhouseCoopers LLP as auditors for 2025 and approved executive compensation on a non-binding basis. Continuity intact.
IPO
Website
Employees
Sector
Industry
DOCS
Doximity, Inc.
43.80-0.85
GEHC
GE HealthCare Technologies Inc.
82.25-2.20
HIMS
Hims & Hers Health, Inc.
36.86+0.61
HYDTF
Hydreight Technologies Inc
3.10-0.06
LFMD
LifeMD, Inc.
3.42+0.15
MGRX
Mangoceuticals, Inc.
1.20+0.06
NXDR
Nextdoor Holdings, Inc.
2.23+0.07
OPRX
OptimizeRx Corporation
12.77-0.41
PETS
PetMed Express, Inc.
3.90+1.03
TDOC
Teladoc Health, Inc.
7.41+0.07